SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Furthering cell therapy ambition across oncology and autoimmune diseases
Decision on EU marketing authorisation expected for momelotinib by early 2024
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Subscribe To Our Newsletter & Stay Updated
